Ginkgo Bioworks Holdings (DNA) Cost of Revenue (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has 7 years of Cost of Revenue data on file, last reported at $3.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 24.25% year-over-year to $3.1 million; the trailing twelve-month figure through Mar 2026 stood at -$8.9 million (up 40.55% YoY), and the FY2021 full-year result was $20.0 million, up 124.76% from the prior year.
• Cost of Revenue for Q1 2026 stood at $3.1 million, up from -$25.6 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $77.3 million in Q1 2022 and bottomed at -$160.8 million in Q4 2022.
• The 5-year median for Cost of Revenue is $4.1 million (2025), against an average of -$6.4 million.
• Peak annual rise in Cost of Revenue reached 678.43% in 2022, while the deepest fall reached 3427.79% in 2022.
• A 5-year view of Cost of Revenue shows it stood at -$160.8 million in 2022, then surged by 70.53% to -$47.4 million in 2023, then soared by 34.6% to -$31.0 million in 2024, then gained by 17.49% to -$25.6 million in 2025, then surged by 112.11% to $3.1 million in 2026.
• The last three Cost of Revenue figures came in at $3.1 million (Q1 2026), -$25.6 million (Q4 2025), and $8.2 million (Q3 2025), per Business Quant data.

Peer Comparison